Key Features
Wegovy FlexTouch 0.25 mg is a pre-filled, single-patient-use injection pen containing semaglutide, a GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The 0.25 mg dose is used as the initial dose for treatment initiation.
Usage Instructions
Administer once weekly by subcutaneous injection in the abdomen, thigh, or upper arm, on the same day each week. The 0.25 mg dose is intended for treatment initiation and is typically increased gradually according to medical guidance. Use strictly under medical supervision.
Clinical Evidence
Semaglutide has demonstrated significant weight reduction in large-scale clinical trials when combined with reduced-calorie diet and increased physical activity. It works by mimicking GLP-1, helping regulate appetite and caloric intake.
Other Ingredients / Materials
Active ingredient: Semaglutide 0.25 mg per dose. Excipients include disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid/sodium hydroxide (for pH adjustment), and water for injection.
Benefits
Supports clinically proven weight reduction, helps control appetite, convenient once-weekly dosing, easy-to-use pre-filled FlexTouch pen, part of a structured weight management program.
Made in
Denmark
